{"id":3653,"date":"2026-10-07T09:00:00","date_gmt":"2026-10-07T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3653"},"modified":"2026-10-07T19:34:46","modified_gmt":"2026-10-07T23:34:46","slug":"survaxm-misses-overall-phase-iib-survival-endpoint","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3653","title":{"rendered":"SurVaxM Misses Overall Phase IIb Survival Endpoint"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

MimiVax<\/p>\n

Event Type<\/strong><\/p>\n

Phase 2b topline result (primary endpoint missed; subgroup signal)<\/p>\n

Modality<\/strong><\/p>\n

Peptide cancer vaccine (survivin-targeted)<\/p>\n

Asset<\/strong><\/p>\n

SurVaxM<\/p>\n

Target<\/strong><\/p>\n

Survivin<\/p>\n

Disease Area<\/strong><\/p>\n

Newly diagnosed glioblastoma<\/p>\n

Summary<\/h4>\n

MimiVax reported that SurVaxM plus standard therapy did not meet the overall-survival primary endpoint in the randomized Phase IIb SURVIVE trial for newly diagnosed glioblastoma. A prespecified age-65-or-younger subgroup showed improved survival and progression-free survival. The primary miss governs the top-line interpretation; the subgroup is hypothesis-strengthening, not a substitute for the overall result.<\/p>\n

SURVIVE evaluated 233 patients at 11 U.S. centers. Median overall survival was 22.8 months with SurVaxM versus 20.3 months with placebo: adjusted hazard ratio 0.75, 95% CI 0.54\u20131.03, p=0.076. In the prespecified subgroup aged 65 or younger, median survival was 24.2 versus 20.2 months, hazard ratio 0.64, 95% CI 0.44\u20130.93, p=0.019; progression-free-survival hazard ratio was 0.64, p=0.018.<\/p>\n

The company reported a favorable late-survival pattern, but the release did not provide a complete multiplicity framework or detailed at-risk tables. The 20.3-month control median exceeded the historical assumption cited by the company.<\/p>\n

Deep Analysis<\/h4>\n

The randomized control matters in glioblastoma, where evolving care, prognostic selection and post-progression therapy can make historical benchmarks unreliable. A hazard ratio of 0.75 suggests possible benefit, but the confidence interval includes no effect and the prespecified primary test did not meet the conventional threshold. The stronger contemporary control is itself an important trial-design lesson.<\/p>\n

Interpretation A is a real effect diluted by biological or age-related heterogeneity. The younger subgroup, aligned survival and progression-free-survival hazard ratios and reported late tail support it. Interpretation B is a false-positive or exaggerated subgroup result after an overall miss. Subset size, possible multiplicity, age as a surrogate for fitness and incomplete tail denominators support caution. The release does not establish a predictive biomarker or immune-response correlate.<\/p>\n

Competitive relevance now depends on whether an identifiable population can be prospectively selected and confirmed. A regulator-accepted analysis plan, independent full publication, immune correlates and a confirmatory trial powered for the subgroup would upgrade the thesis. Loss of the effect after multiplicity adjustment, inconsistent geography, imbalanced subsequent therapy or failure to reproduce would downgrade it.<\/p>\n

Company and Product Background<\/h4>\n

Glioblastoma is an aggressive primary brain tumor treated with surgery, radiation and temozolomide, with frequent recurrence. SurVaxM is a peptide vaccine designed to induce immune responses against survivin, an anti-apoptotic protein expressed in many tumors. Vaccine activity depends on antigen presentation, T-cell function, tumor heterogeneity and the immunosuppressive brain-tumor microenvironment.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Overall primary OS endpoint missed: HR 0.75, p=0.076.<\/li>\n
  • Prespecified age \u226465 subgroup: OS HR 0.64, p=0.019; PFS HR 0.64, p=0.018.<\/li>\n
  • Contemporaneous control outperformed the historical assumption.<\/li>\n
  • Long-tail survival is company-reported and requires at-risk denominators and full analysis.<\/li>\n
  • Next evidence: peer-reviewed dataset, multiplicity plan, biomarker analysis and prospective confirmation.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    SURVIVE is mixed, with a negative overall primary test and a potentially important younger-patient signal. The subgroup deserves mechanistic and confirmatory work, but a directional claim stronger than \u201chypothesis-strengthening\u201d would outrun the current evidence.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: mixed; negative for the overall primary endpoint and positive within the reported younger subgroup. Confidence in Facts: high. Confidence in Interpretation: moderate-low. Missing facts include complete hierarchy and multiplicity, baseline subgroup balance, immune correlates, treatment after progression and tail-risk tables. Red-team: a prespecified subgroup can still mislead when the primary endpoint fails and several analyses are examined.<\/p>\n","protected":false},"excerpt":{"rendered":"

    MimiVax reported that SurVaxM plus standard therapy did not meet the overall-survival primary endpoint in the randomized Phase IIb SURVIVE trial for newly diagnosed glioblastoma. A prespecified age-65-or-younger subgroup showed improved survival and progression-free…<\/p>\n","protected":false},"author":1,"featured_media":3654,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[992,253,988,989,991,990],"class_list":["post-3653","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-cancer-vaccine","tag-glioblastoma","tag-mimivax","tag-survaxm","tag-survive","tag-survivin"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3653"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3653\/revisions"}],"predecessor-version":[{"id":3667,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3653\/revisions\/3667"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3654"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}